» Articles » PMID: 21384047

Methoxy-derivatization of Alkyl Chains Increases the in Vivo Efficacy of Cationic Mn Porphyrins. Synthesis, Characterization, SOD-like Activity, and SOD-deficient E. Coli Study of Meta Mn(III) N-methoxyalkylpyridylporphyrins

Overview
Journal Dalton Trans
Specialty Chemistry
Date 2011 Mar 9
PMID 21384047
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Cationic Mn(III) N-alkylpyridylporphyrins (MnPs) are potent SOD mimics and peroxynitrite scavengers and diminish oxidative stress in a variety of animal models of central nervous system (CNS) injuries, cancer, radiation, diabetes, etc. Recently, properties other than antioxidant potency, such as lipophilicity, size, shape, and bulkiness, which influence the bioavailability and the toxicity of MnPs, have been addressed as they affect their in vivo efficacy and therapeutic utility. Porphyrin bearing longer alkyl substituents at pyridyl ring, MnTnHex-2-PyP(5+), is more lipophilic, thus more efficacious in vivo, particularly in CNS injuries, than the shorter alkyl-chained analog, MnTE-2-PyP(5+). Its enhanced lipophilicity allows it to accumulate in mitochondria (relative to cytosol) and to cross the blood-brain barrier to a much higher extent than MnTE-2-PyP(5+). Mn(III) N-alkylpyridylporphyrins of longer alkyl chains, however, bear micellar character, and when used at higher levels, become toxic. Recently we showed that meta isomers are ∼10-fold more lipophilic than ortho species, which enhances their cellular accumulation, and thus reportedly compensates for their somewhat inferior SOD-like activity. Herein, we modified the alkyl chains of the lipophilic meta compound, MnTnHex-3-PyP(5+) via introduction of a methoxy group, to diminish its toxicity (and/or enhance its efficacy), while maintaining high SOD-like activity and lipophilicity. We compared the lipophilic Mn(III) meso-tetrakis(N-(6'-methoxyhexyl)pyridinium-3-yl)porphyrin, MnTMOHex-3-PyP(5+), to a hydrophilic Mn(III) meso-tetrakis(N-(2'-methoxyethyl)pyridinium-3-yl)porphyrin, MnTMOE-3-PyP(5+). The compounds were characterized by uv-vis spectroscopy, mass spectrometry, elemental analysis, electrochemistry, and ability to dismute O(2)˙(-). Also, the lipophilicity was characterized by thin-layer chromatographic retention factor, R(f). The SOD-like activities and metal-centered reduction potentials for the Mn(III)P/Mn(II)P redox couple were similar-to-identical to those of N-alkylpyridyl analogs: log k(cat) = 6.78, and E(1/2) = +68 mV vs. NHE (MnTMOHex-3-PyP(5+)), and log k(cat) = 6.72, and E(1/2) = +64 mV vs. NHE (MnTMOE-3-PyP(5+)). The compounds were tested in a superoxide-specific in vivo model: aerobic growth of SOD-deficient E. coli, JI132. Both MnTMOHex-3-PyP(5+) and MnTMOE-3-PyP(5+) were more efficacious than their alkyl analogs. MnTMOE-3-PyP(5+) is further significantly more efficacious than the most explored compound in vivo, MnTE-2-PyP(5+). Such a beneficial effect of MnTMOE-3-PyP(5+) on diminished toxicity, improved efficacy and transport across the cell wall may originate from the favorable interplay of the size, length of pyridyl substituents, rotational flexibility (the ortho isomer, MnTE-2-PyP(5+), is more rigid, while MnTMOE-3-PyP(5+) is a more flexible meta isomer), bulkiness and presence of oxygen.

Citing Articles

Antibacterial Activity of Synthetic Cationic Iron Porphyrins.

Tovmasyan A, Batinic-Haberle I, Benov L Antioxidants (Basel). 2020; 9(10).

PMID: 33050461 PMC: 7601463. DOI: 10.3390/antiox9100972.


Mn Porphyrin-Based Redox-Active Drugs: Differential Effects as Cancer Therapeutics and Protectors of Normal Tissue Against Oxidative Injury.

Batinic-Haberle I, Tovmasyan A, Spasojevic I Antioxid Redox Signal. 2018; 29(16):1691-1724.

PMID: 29926755 PMC: 6207162. DOI: 10.1089/ars.2017.7453.


Metal complexes as potential modulators of inflammatory and autoimmune responses.

Leung C, Lin S, Zhong H, Ma D Chem Sci. 2017; 6(2):871-884.

PMID: 28660015 PMC: 5472922. DOI: 10.1039/c4sc03094j.


Challenges encountered during development of Mn porphyrin-based, potent redox-active drug and superoxide dismutase mimic, MnTnBuOE-2-PyP, and its alkoxyalkyl analogues.

Rajic Z, Tovmasyan A, de Santana O, Peixoto I, Spasojevic I, do Monte S J Inorg Biochem. 2017; 169:50-60.

PMID: 28131001 PMC: 5893775. DOI: 10.1016/j.jinorgbio.2017.01.003.


Anticancer therapeutic potential of Mn porphyrin/ascorbate system.

Tovmasyan A, Sampaio R, Boss M, Bueno-Janice J, Bader B, Thomas M Free Radic Biol Med. 2015; 89:1231-47.

PMID: 26496207 PMC: 4684782. DOI: 10.1016/j.freeradbiomed.2015.10.416.


References
1.
Nam W, Jin S, Lim M, Ryu J, Kim C . Anionic ligand effect on the nature of epoxidizing intermediates in iron porphyrin complex-catalyzed epoxidation reactions. Inorg Chem. 2002; 41(14):3647-52. DOI: 10.1021/ic011145p. View

2.
Spasojevic I, Batinic-Haberle I, Stevens R, Hambright P, Thorpe A, Grodkowski J . Manganese(III) biliverdin IX dimethyl ester: a powerful catalytic scavenger of superoxide employing the Mn(III)/Mn(IV) redox couple. Inorg Chem. 2001; 40(4):726-39. DOI: 10.1021/ic0004986. View

3.
Trostchansky A, Ferrer-Sueta G, Batthyany C, Botti H, Batinic-Haberle I, Radi R . Peroxynitrite flux-mediated LDL oxidation is inhibited by manganese porphyrins in the presence of uric acid. Free Radic Biol Med. 2003; 35(10):1293-300. DOI: 10.1016/j.freeradbiomed.2003.07.004. View

4.
Jin N, Lahaye D, Groves J . A "push-pull" mechanism for heterolytic o-o bond cleavage in hydroperoxo manganese porphyrins. Inorg Chem. 2010; 49(24):11516-24. DOI: 10.1021/ic1015274. View

5.
Batinic-Haberle I, Rajic Z, Tovmasyan A, Reboucas J, Ye X, Leong K . Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics. Free Radic Biol Med. 2011; 51(5):1035-53. PMC: 3178885. DOI: 10.1016/j.freeradbiomed.2011.04.046. View